<div id="readability-page-1"><div><p>(MT Newswires) -- China's medical product administrator approved Guangxi Wuzhou Zhongheng's (SHA:600252) nicorandil tablets and ketorolac tromethamine injection, according to a Thursday filing with the Shanghai bourse.</p><p> The nicorandil tablets are indicated for angina pectoris or chest pain, while the ketorolac tromethamine injection is indicated for post-operative pain relief, the filing said.</p><p>Shares fell 1% during afternoon trading on Thursday.</p></div></div>

中恆集團

<p>（MT Newswires）-- 根據週四在上海證券交易所的文件，中國醫療產品管理局批准了廣西梧州中恆（SHA:600252）的硝苯地平片和酮咯酸託瑞米芬注射液。文件指出，硝苯地平片適用於心絞痛或胸痛，而酮咯酸託瑞米芬注射液適用於術後鎮痛。週四下午交易中，股價下跌了 1%</p>

廣西梧州中恆集團獲得中國批准用於治療胸部和術後疼痛的藥物